Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098501 · ClinicalTrials.gov registry record · Phase 1
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00098501: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00098501 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00098501, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects, best way to give, and best dose of CCI-779 and EKB-569 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. EKB-569 may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving CCI-779 together with EKB-569 may kill more tumor cells.
Interventions
- DRUG temsirolimus
- DRUG pelitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098501
The ClinicalTrials.gov registry entry for NCT00098501 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temsirolimus is the first listed.
NCT00098501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098501 about?
NCT00098501 is a clinical study titled "CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors". This phase I trial is studying the side effects, best way to give, and best dose of CCI-779 and EKB-569 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping t...
What is the current status of trial NCT00098501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00098501?
The interventions under investigation include: temsirolimus (DRUG), pelitinib (DRUG).
Who is sponsoring clinical trial NCT00098501?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.